stockportfolio.pro
UTHR vs VTRS: Which Stock Is the Better Buy?
United Therapeutics Corporation and Viatris Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — UTHR vs VTRS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| United Therapeutics Corporation (UTHR) | Viatris Inc. (VTRS) | |
|---|---|---|
| Market cap | $23.0B | $19.4B |
| Revenue (latest FY) | $3.18B | $14.30B |
| Net income (latest FY) | $1.33B | $-3.51B |
| Revenue growth (5y CAGR) | 16.5% | 3.7% |
| Net margin | 41.9% | -24.6% |
| Return on equity | 18.8% | -23.9% |
| P/E ratio | 20.0 | — |
| Dividend yield | — | 2.9% |
| Profitable years (of last 10) | 8 | 4 |
| Positive free cash flow | Yes | Yes |
See the full UTHR vs VTRS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open UTHR's full financials → Open VTRS's full financials →More comparisons
Frequently asked questions
Which is bigger, UTHR or VTRS?
United Therapeutics Corporation is larger by market capitalization — $23.0B versus $19.4B.
Which grows faster, UTHR or VTRS?
Over the last five fiscal years, United Therapeutics Corporation grew revenue faster — 16.5%/yr versus 3.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.